HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Heterozygosity for a coding SNP in COL1A2 confers a lower BMD and an increased stroke risk.

Abstract
Genetic variation plays an important role in osteoporosis and a prime candidate gene is Collagen alpha2(I) (COL1A2). A coding polymorphism (rs42524) in COL1A2 has previously been associated with intracranial aneurysms. Here the effects of this polymorphism have been studied in relation to bone mineral density (BMD) and prevalences of stroke and myocardial infarction (MI). rs42524 was genotyped in elderly men (n = 2004) from the Swedish MrOS cohort. Genotypes were analysed for association to BMD and certain health parameters. Significant associations (overall P < 0.05), were observed between rs42524 genotype and BMD at several skeletal sites. Surprisingly, the heterozygote genotype class exhibited lower BMD than either homozygote group. When subjects were classified as heterozygotes or homozygotes, the heterozygous genotype was found to confer a lower BMD at total hip, femoral neck and trochanter Furthermore, the heterozygote genotype had an increased risk of stroke and MI, with population Attributable Risks being 0.12 and 0.08, respectively.
AuthorsKatarina Lindahl, Carl-Johan Rubin, Helena Brändström, Magnus K Karlsson, Anna Holmberg, Claes Ohlsson, Dan Mellström, Eric Orwoll, Hans Mallmin, Andreas Kindmark, Osten Ljunggren
JournalBiochemical and biophysical research communications (Biochem Biophys Res Commun) Vol. 384 Issue 4 Pg. 501-5 (Jul 10 2009) ISSN: 1090-2104 [Electronic] United States
PMID19426706 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Collagen Type I
  • Collagen
Topics
  • Aged
  • Bone Density (genetics)
  • Cohort Studies
  • Collagen (genetics)
  • Collagen Type I
  • Heterozygote
  • Humans
  • Male
  • Polymorphism, Single Nucleotide
  • Risk
  • Stroke (epidemiology, genetics)
  • Sweden (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: